Citations

Clear

3042 citation(s) found for "Kumar, S".

Coordination of Centrosome Homeostasis and DNA Repair Is Intact in MCF-7 and Disrupted in MDA-MB 231 Breast Cancer Cells
Acu, Ilie D., Liu, Tieju , Suino-Powell, Kelly, Mooney, Steven M. , D’Assoro, Antonino B. , Correa, Ricardo G. , Niu, Yun , Kumar, Rajiv , Salisbury, Jeffrey L., Rowland, Nicholas James , Muotri, Alysson Renato , Kumar, Rajiv

Mayo Clinic

Cancer Research | April 13, 2010 | Volume: 70 | Issue: 8 | Pages: 3320-3328

10.1158/0008-5472.can-09-3800 | PMID 20388771 Get It

Abstract When cells encounter substantial DNA damage, critical cell cycle events are halted while DNA repair mechanisms are activated to restore genome integrity. Genomic integrity also depends on proper assembly and function of the bipolar mitotic spindle, which is required for equal chromosome segregation. Failure to execute either of these processes leads to genomic instability, aging, and cancer. Here, we show that following DNA damage in the breast cancer cell line MCF-7, the centrosome protein centrin2 moves from the cytoplasm and accumulates in the nucleus in a xeroderma pigmentosum complementation group C protein (XPC)–dependent manner, reducing the available cytoplasmic pool of this key centriole protein and preventing centrosome amplification. MDA-MB 231 cells do not express XPC and fail to move centrin into the nucleus following DNA damage. Reintroduction of XPC expression in MDA-MB 231 cells rescues nuclear centrin2 sequestration and reestablishes control against centrosome amplification, regardless of mutant p53 status. Importantly, the capacity to repair DNA damage was also dependent on the availability of centrin2 in the nucleus. These observations show that centrin and XPC cooperate in a reciprocal mechanism to coordinate centrosome homeostasis and DNA repair and suggest that this process may provide a tractable target to develop treatments to slow progression of cancer and aging. Cancer Res; 70(8); 3320–8. ©2010 AACR.
Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis
Dingli, David , Kumar, Shaji , Dispenzieri, Angela , Hayman, Suzanne R. , Lacy, Martha Q. , Gastineau, D A, Tan, Timothy Shao Ern , Buadi, Francis K. , Hogan, William J. , Gertz, Morie A. , Dispenzieri, Angela , Dingli, David

Mayo Clinic

Neurology | March 15, 2010 | Volume: 74 | Issue: 11 | Pages: 913-918

10.1212/wnl.0b013e3181d55f4d | PMID 20231668 Get It

Spontaneous Tumor Lysis Syndrome in the Setting of B-Cell Lymphoma
Figanbaum, Travis, Ghosh, Amit Kumar , Caples, Sean M., Opyrchal, Mateusz , Figanbaum, Travis L., Rajkumar, S. Vincent

Mayo Clinic

Case Reports in Medicine | March 11, 2010 | Volume: 2010 | Issue: No issue available | Pages: 1-3

10.1155/2010/610969 | PMID 20300188 Get It

Tumor lysis syndrome (TLS) presenting in absence of chemotherapy is a rare occurrence. One of the true oncological emergencies, it can lead to significant morbidity and mortality. TLS is a phenomena usually associated with tumor cell death after treatment. The etiology of the spontaneous TLS is not well understood, which complicates the diagnosis. TLS is well known to oncologists but physicians outside of this specialty have little or no experience with this condition. Early recognition and treatment are the keys to limiting the sequela of the condition. Spontaneous tumor lysis syndrome is rare but presents added risks to the patient because of the potential for delayed diagnosis and no benefit of pretreatment. Diagnosis may be further delayed because this may be the first symptom of underlying malignancy. Therefore, it is imperative that all clinicians are familiar with the syndrome to assure timely recognition.
Effect of 1,25-dihydroxyvitamin D3 on mouse mammary tumor (GR) cells: Evidence for receptors, cellular uptake, inhibition of growth and alteration in morphology at physiologic concentrations of hormone
Gross, Myron D., Kost, Susan Bollman, Ennis, Bruce W., Stumpf, Walter E., Kumar, Rajiv , Kumar, Rajiv

Mayo Clinic

Journal of Bone and Mineral Research | February 3, 2010 | Volume: 1 | Issue: 5 | Pages: 457-467

10.1002/jbmr.5650010510 | PMID 2845731 Get It

Abstract Mammary glands are target tissues for 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). We have examined a mouse mammary tumor cell line (GR) for receptors of 1,25(OH)2D3 and have examined alterations in the growth and morphology of these cells in response to 1,25(OH)2D3. GR cells contain a high affinity (Kd ∼ 10−11), lowcapacity receptor with a high specificity for 1,25(OH)2D3. The 1,25(OH)2D3 receptor in GR cells has a sedimentation coefficient of 3.5 and elutes from DEAE cellulose columns with ∼ 0.15 M KCI. These properties of the receptor are similar to those reported for other 1,25(OH)2D3 receptors. 1,25(OH)2D3 is internalized by GR cells in situ and specifically bound 1,25(OH)2D3 is found predominantly, if not entirely, in the nucleus as determined by cell fractionation and autoradiographic techniques. The incubation of GR cells in culture for 7 days with 1,25(OH)2D, markedly alters cell growth. Cell growth is retarded in a dose-dependent manner; physiologic concentrations (10−10M) of l,25(OH)2D3 retard cell growth by approximately 50%. In addition, GR cells incubated with 10−9 to 10−8M 1,25(OH)2D3 undergo marked morphological changes. The incubation of GR cells with other vitamin D metabolites such as 25-hydroxyvitamin D3 (25(OH)D3) at a concentration of 10−9M does not significantly alter cell growth or morphology. The presence of high affinity receptors for 1,25(OH)2D3, the specific internalization of 1,25(OH)2D3 predominantly into the nuclei, and the significant effects of physiological concentrations of 1,25(OH)2D3 on cell growth suggest a direct, specific, nuclear effect of 1,25(OH)2D3 on GR cells. The mouse mammary tumor model might be useful in examining the effect of 1,25(OH)2D3 on tumor formation.
Interrelationship among vitamin D metabolism, true calcium absorption, parathyroid function, and age in women: Evidence of an age-related intestinal resistance to 1,25-dihydroxyvitamin D action
Eastell, Richard , Yergey, Alfred L. , Vieira, Nancy E., Cedel, Sandra L., Kumar, Rajiv , Riggs, Bruce, Kumar, Rajiv

Mayo Clinic

Journal of Bone and Mineral Research | February 3, 2010 | Volume: 6 | Issue: 2 | Pages: 125-132

10.1002/jbmr.5650060205 | PMID 2028834 Get It

Abstract We studied the mechanism of impaired calcium absorption with aging in 51 healthy women whose ages ranged from 26 to 88 years. Serum concentrations of 1,25-dihydroxyvitamin D [1,25-(OH)2D, mean of four measurements per subject] increased with age by 22% (P < 0.05) but, by split-point analysis, plateaued or decreased slightly after age 65. In a subset of 20 subjects, [3H]1,25-(OH)2D3 kinetic analysis showed that this increase with age resulted from both increased production and decreased metabolic clearance of 1,25-(OH)2D. Despite the increase in serum 1,25-(OH)2D concentration, true calcium absorption did not change with age. The expected inverse correlation between true fractional calcium absorption and dietary calcium intake, however, was easily demonstrated (r = 0.66, P < 0.001). Serum intact parathyroid hormone (PTH) increased with age by 35% (P < 0.02) and serum bone gla protein (BGP, osteocalcin) increased by 47% (P < 0.001); the increases in serum PTH and serum BGP were directly correlated (r = 0.32, P < 0.05). The data are consistent with the following hypothetical model: (1) intestinal resistance to 1,25-(OH)2D action accounts for the increase in serum 1,25-(OH)2D concentrations with aging with no change in true calcium absorption; (2) this results in a compensatory increase in PTH secretion and in 1,25-(OH)2D production that prevents true calcium absorption from decreasing; (3) the previously described defect in 25-hydroxyvitamin D (25-OHD) 1α-hydroxylase activity in aging animals and humans acccounts for the leveling off in serum 1,25-(OH)2D concentration after age 65 years; and (4) the secondary hyperparathyroidism leads to increased bone turnover and thus contributes to age-related bone loss.
Molecular Cloning Of A Plasma Membrane Calcium Pump From Human Osteoblasts
Kumar, Rajiv , Haugen, James D., Penniston, John T., Kumar, Rajiv

Mayo Clinic

Journal of Bone and Mineral Research | February 3, 2010 | Volume: 8 | Issue: 4 | Pages: 505-513

10.1002/jbmr.5650080415 | PMID 8386431 Get It

Abstract The osteoblast plays a critical role in bone formation, bone remodeling, bone matrix formation, and matrix calcification. To better understand the process of osteoblast-controlled bone formation, we determined the structure and isoform types of the plasma membrane calcium pump from normal human osteoblasts. A complementary DNA library from normal human osteoblasts was screened for plasma membrane calcium pump clones. Sequencing and analysis of cDNA clones revealed the presence of a 3986 base pair cDNA that encoded a 1220 amino acid protein that was similar to the human plasma membrane calcium pump isoform 1. Polyadenylated RNA from human osteoblast cells contains bands of RNA approximately 5050 and 6750 bases long. Reverse transcription of polyadenylated RNA from human osteoblasts followed by amplification of the RNA-DNA duplex with calcium pump isoform-specific primers revealed the presence of isoforms 1 and 2 of the calcium pump. Isoform 4 was not detected. We conclude that normal adult human osteoblasts contain a plasma membrane calcium pump that is similar to the human plasma membrane calcium pump isoform 1. It is likely that this pump plays an important role in the cell biology of the human osteoblast.
Ontogeny of the 1,25-dihydroxyvitamin D3 receptor in fetal rat bone
Grande, Joseph P. , Roche, Patrick C. , Kumar, Rajiv , Johnson, Julie A. , Kumar, Rajiv

Mayo Clinic

Journal of Bone and Mineral Research | February 3, 2010 | Volume: 11 | Issue: 1 | Pages: 56-61

10.1002/jbmr.5650110109 | PMID 8770697 Get It

Abstract To gain insights into 1,25-dihydroxyvitamin D3 receptor (VDR) function during fetal bone development, we examined fetal rat tissues from gestational days 13–21 for the presence and distribution of VDR using immuno-histochemistry. Prior to ossification, VDR epitopes were observed in the mesenchyme condensing to form skeletal tissues, on day 13 in the developing vertebral column and limbs, and on day 17 of gestation in developing calvaria. Immunostaining for VDR was seen in proliferating and hypertrophic chondrocytes and in osteoblasts of limb buds and the vertebral column by day 17 of gestation. In calvaria, VDR epitopes were observed in osteoblasts by gestational day 19. VDR immunostaining was also evident in the skin of fetal limbs at all gestational ages examined. We show for the first time that the VDR appears very early in the developing fetal rat skeleton, suggesting that the VDR, in concert with its ligand, 1,25-dihydroxyvitamin D3, may play a role in the differentiation of mesenchymal precursors into bone tissue.
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction
Kumar, Shaji , Lacy, Martha Q. , Dispenzieri, Angela , Dingli, David , Hayman, Suzanne R. , Gertz, Morie A. , Buadi, Francis K. , Hogan, William J. , Dispenzieri, Angela , Dingli, David

Mayo Clinic

Blood | January 21, 2010 | Volume: 115 | Issue: 12 | Pages: 2348-2353

10.1182/blood-2009-07-235531 | PMID 20089967 Get It

Autologous stem cell transplantation as a platform for multiple myeloma treatment is the standard of care for patients who can safely withstand the procedure. Before novel agents were introduced, one-third to one-half of patients did not achieve partial response at transplantation. Previous medical literature has shown that in this past era, absence of initial response to induction therapy had no impact on progression-free survival and overall survival after high-dose therapy. Lack of response to initial induction did not preclude a good response after stem cell transplantation. With the introduction of novel agents—immunomodulatory drugs and proteasome inhibitors—response rates with initial therapy are now between 70% and 100%. This retrospective study analyzes progression-free survival and overall survival in patients who do not have a partial response (never responded or progressed during continuous therapy) after induction therapy with a regimen that contains thalidomide or lenalidomide. Unlike patients in reports published previously—before immunomodulatory drugs—patients who do not achieve partial remission have a significantly shorter overall survival from transplantation (73.5 vs 30.4 months) and a shorter progression-free survival (22.1 vs 13.1 months; P < .001). Absence of a response to induction therapy with thalidomide or lenalidomide predicts a poorer outcome after high-dose therapy.
A Stimulatory Thyrotropin Receptor Antibody (M22) and Thyrotropin Increase Interleukin-6 Expression and Secretion in Graves' Orbital Preadipocyte Fibroblasts
Kumar, Seema , Schiefer, Reagan, Coenen, Michael J., Bahn, Rebecca S.

Mayo Clinic

Thyroid | December 17, 2009 | Volume: 20 | Issue: 1 | Pages: 59-65

10.1089/thy.2009.0278 | PMID 20017620 Get It

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
Gay, Francesca , Hayman, Suzanne R. , Lacy, Martha Q. , Kumar, Shaji , Dispenzieri, Angela , Bergsagel, P. Leif , Dingli, David , Reeder, Craig B. , Lust, John A., Russell, Stephen J. , Zeldenrust, Steven R., Fonseca, Rafaël , Kyle, Robert A. , Greipp, Philip R., Stewart, A. Keith, Rajkumar, S. Vincent , Buadi, Francis K. , Gertz, Morie A. , Mıkhael, Joseph , Roy, Vivek , Witzig, Thomas E. , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Gay, Francesca , Fonseca, Rafael

Mayo Clinic

Blood | December 12, 2009 | Volume: 115 | Issue: 7 | Pages: 1343-1350

10.1182/blood-2009-08-239046 | PMID 20008302 Get It

AbstractThe objective of this case-control study was to compare the efficacy and toxicity of lenalidomide plus dexamethasone (len/dex) versus thalidomide plus dexamethasone (thal/dex) as initial therapy for newly diagnosed myeloma. We retrospectively studied 411 newly diagnosed patients treated with len/dex (228) or thal/dex (183) at the Mayo Clinic. The differences were similar in a matched-pair analysis that adjusted for age, sex, transplantation status, and dexamethasone dose. The proportions of patients achieving at least a partial response to len/dex and thal/dex were 80.3% versus 61.2%, respectively (P < .001); very good partial response rates were 34.2% and 12.0%, respectively (P < .001). Patients receiving len/dex had longer time to progression (median, 27.4 vs 17.2 months; P = .019), progression-free survival (median, 26.7 vs 17.1 months; P = .036), and overall survival (median not reached vs 57.2 months; P = .018). A similar proportion of patients in the 2 groups experienced at least one grade 3 or 4 adverse event (57.5% vs 54.6%, P = .568). Main grade 3 or 4 toxicities of len/dex were hematologic, mainly neutropenia (14.6% vs 0.6%, P < .001); the most common toxicities in thal/dex were venous thromboembolism (15.3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results.